News >

MDS Armamentarium Expands With Luspatercept Approval, Novel Compounds

Caroline Seymour
Published: Monday, Apr 06, 2020

David P. Steensma, MD, associate professor of medicine, Harvard Medical School, clinic director, Center for Prevention of Progression, Edward P. Evans Chair in Myelodysplastic Syndromes Research, and institute physician, Dana-Farber Cancer Institute

David P. Steensma, MD

The armamentarium in myelodysplastic syndromes (MDS) is slated to grow with agents such as luspatercept-aamt (Reblozyl), venetoclax (Venclexta), APR-246, and magrolimab, despite some of the challenges with drug development in the space, explained David P. Steensma, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication